Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 28, 2023	Feb. 28, 2022	Feb. 28, 2023	Feb. 28, 2022
Operating activities:
Net earnings	$ 50,258	$ 58,647	$ 135,007	$ 313,307
Adjustments to reconcile net earnings to net cash provided (used) by operating activities:
Depreciation and amortization	28,153	27,425	84,508	70,579
Impairment of long-lived assets	484	3,076	796	3,076
Provision for (benefit from) deferred income taxes	(5,525)	10,661	(20,198)	13,336
Bad debt expense	2,346	382	3,786	896
Equity in net income of unconsolidated affiliates, net of distributions	23,218	(18,604)	84,415	(83,096)
Net loss (gain) on sale of assets	46	(628)	(4,988)	(13,830)
Stock-based compensation	4,975	4,408	13,758	11,959
Changes in assets and liabilities, net of impact of acquisitions:
Receivables	3,382	(33,766)	160,475	(155,451)
Inventories	53,499	31,051	166,959	(229,813)
Accounts payable	6,627	51,893	(195,489)	50,967
Accrued compensation and employee benefits	(2,900)	(21,105)	(33,432)	(52,924)
Income taxes payable		(14,422)	(300)	(1,487)
Other operating items, net	17,588	(24,828)	833	(22,245)
Net cash provided (used) by operating activities	182,151	74,190	396,130	(94,726)
Investing activities:
Investment in property, plant and equipment	(22,748)	(23,645)	(68,715)	(71,804)
Investment in non-marketable equity securities	(20)		(270)
Acquisitions, net of cash acquired		(269,511)	(56,088)	(377,261)
Net proceeds from sale of investment in ArtiFlex	(300)		35,795
Proceeds from sale of assets, net of selling costs	51	4,083	35,545	35,904
Net cash used by investing activities	(23,017)	(289,073)	(53,733)	(413,161)
Financing activities:
Net proceeds from (repayments of) short-term borrowings	(1,330)	105,638	(44,392)	105,638
Principal payments on long-term obligations	(5,759)	(152)	(5,909)	(554)
Proceeds from issuance of common shares, net of tax withholdings	704	269	(3,411)	(6,516)
Payments to noncontrolling interests		(3,360)	(11,760)	(15,436)
Repurchase of common shares		(54,255)		(127,842)
Dividends paid	(15,101)	(14,127)	(44,166)	(43,390)
Net cash provided (used) by financing activities	(21,486)	34,013	(109,638)	(88,100)
Increase (decrease) in cash and cash equivalents	137,648	(180,870)	232,759	(595,987)
Cash and cash equivalents at beginning of period	129,596	225,194	34,485	640,311
Cash and cash equivalents at end of period	$ 267,244	$ 44,324	$ 267,244	$ 44,324